Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SAN DIEGO, June 17, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
-
– Study met primary efficacy endpoint with statistical significance after 24 weeks of treatment – – Safety data are supportive of differentiated product profile...
-
- Top-line results of Phase 2 trial of RPC1063 in relapsing multiple sclerosis expected in mid-2014 - - Phase 3 trial of RPC1063 in relapsing multiple sclerosis enrolling patients globally -...
-
SAN DIEGO, May 7, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce...
-
SAN DIEGO, May 6, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
-
SAN DIEGO, May 1, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
-
SAN DIEGO, April 28, 2014 (GLOBE NEWSWIRE) -- Receptos Inc. (Nasdaq:RCPT) today announced that Company personnel will deliver two scientific poster presentations regarding its lead program, RPC1063,...
-
SAN DIEGO, April 14, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
-
SAN DIEGO, March 20, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
-
- Favorable interim results from Phase 2 trial of RPC1063 in relapsing multiple sclerosis consistent with differentiated profile; top-line data expected mid-2014 - - Phase 3 trial of RPC1063 in...